# A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

> **NCT02091999** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 213 (actual)

## Conditions studied

- Metastatic Urothelial Cancer and Other Malignant Solid Tumors

## Interventions

- **DRUG:** enfortumab vedotin

## Key facts

- **NCT ID:** NCT02091999
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-14
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091999, "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02091999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*